This site is intended for health professionals only
Wednesday 21 November 2018
Share |

Topic: Patient care

October 17, 2018
Pregabalin and gabapentin will be reclassified as class C drugs next year following a rising numbers of deaths linked to the drugs, the Government has said.

Pregabalin and gabapentin will be reclassified as class C drugs next year following a rising numbers of deaths linked to the drugs, the UK Government has said.
 

August 23, 2018
Working as a pharmacist in the Central African Republic and the Democratic Republic of the Congo was a rewarding experience, despite considerable challenges, explains Barbara Pawulska

Working as a pharmacist in the Central African Republic and the Democratic Republic of the Congo was a rewarding experience, despite considerable challenges, explains Barbara Pawulska
 
What with busy dispensaries and tricky patients to contend with, life as a pharmacist can present challenges in any walk of the profession.
 

August 2, 2018
The Government should consider the economic as well as health benefits of vaccinating people against flu, according to research by a think tank

The Government should consider the economic as well as health benefits of vaccinating people against flu, according to research by a think tank.
 
Research by the International Longevity Centre – UK (ILC-UK) argued that flu can adversely affect productivity within the economy. The biggest economic benefit of vaccinating against the condition is the reduction of lost employment and care giving costs, which total between £90m and £270m , it said.
 

July 26, 2018
How will Matt Hancock’s healthcare priorities benefit the NHS?

Last week, health and social care secretary Matt Hancock gave his first speech at West Suffolk Hospital where he revealed three key priorities for the NHS: technology, workforce and prevention.
 
Speaking before the Health and Social Care Committee yesterday, he also gave more information on the work he intends to do.
 
So what do the priorities mean for the health service?
 
Technology focus
 

June 26, 2018
The guidance recommends co-prescribing cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease, building on broader prescribing advice from the 2006 guidelines. A spokesperson from NICE said that the change was in response to new trials, including the DOMINO-AD trial in the UK.

The UK’s National Institute for health and Care and Excellence (NICE) has updated dementia guidelines to  include revised prescribing advice, new measures for patients suffering from dementia with lewy bodies (DLB) and a move to primary care treatment.
 

June 21, 2018
Targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors

A targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers have found.
 
EZH2 is elevated in immune T cells in patients after treatment with ipilimumab, a team at the University of Texas MD Anderson Cancer Center showed. The drug unleashes an immune response by blocking the activity of CTLA-4 on T cells – white blood cells that serve as the ‘targeted warriors’ of the adaptive immune system.
 

June 1, 2018
Health and Social Care Committee identifies key areas associated with childhood obesity, which demand urgent attention from government

The Health and Social Care Committee has called on the UK government to make it clear that childhood obesity is “everyone’s business”.

 

June 1, 2018
Based on a recent planned review, the Data Monitoring Committee (DMC) recommends termination of Phase Ib/II study of daratumumab plus atezolizumab (anti PD-L1 antibody) in patients with previously treated non-small cell lung cancer

A mid-stage trial involving patients with pre-treated metastatic non-small cell lung cancer has been terminated after a combination of daratumumab (Janssen’s Darzalex) and atezolizumab (Roche’s Tecentriq) failed to show any benefit over the latter alone.
 
 

February 28, 2018
There are 7000 rare diseases affecting an estimated 350 million people globally

February 22, 2018
Rare Disease Day was established in Europe in 2008 by EURORDIS-Rare Diseases Europe, the organisation representing rare disease patients in Europe, and is now observed in more than 90 nations

Shire has announced its continuing global education and awareness efforts on Rare Disease Day 2018, to deliver on its commitment to champion those impacted by rare disease, including patients, families and caregivers.

 

The company is helping to raise awareness about the impact and prevalence of rare diseases, while also listening to and working with an extended community of stakeholders on potential innovative solutions to help reduce the time to diagnosis.

 

January 17, 2018
The aim of the needle exchange service throughout the UK is to reduce the rates of used needle sharing among drug users, preventing the risks of infection and drug-related harm

Addaction in Lincolnshire, UK have adapted a familiar piece of equipment - the vending machine - into a first-in-the-UK, pharmacy -based pilot to dispense clean needles for drug users.

 

The dispenser has been installed in a Sleaford pharmacy to address a limited provision in the area. 

 

The aim of the needle exchange service throughout the UK is to reduce the rates of used needle sharing among drug users, preventing the risks of infection and drug-related harm.

 

May 17, 2016
UC CARES Study reveals one in four patients report unmet clinical needs, severe quality of life and work productivity impairment when treated with conventional therapies

MSD, known as Merck & Co., Inc., Kenilworth, NJ, USA in the United States and Canada, announced the publication of two papers1 for the pan-European Ulcerative Colitis Condition, Attitude, Resources and Educational Study (UC CARES), the first study conducted to assess patients’ perception of disease burden and unmet clinical needs in moderate-to-severe ulcerative colitis (UC).2
 

May 13, 2016
First Fc Fusion therapy approved for haemophilia B in the EU to provide extended protection against bleeds

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Biogen announced that the European Commission (EC) has approved Alprolix® (rFIXFc), their extended half-life therapy, for the treatment of haemophilia B in all 28 European Union (EU) Member States and maintained its orphan designation. Alprolix is the only recombinant factor IX Fc Fusion protein therapy for haemophilia B to offer people in the EU prolonged protection against bleeding episodes with fewer prophylactic injections.

May 4, 2016
Hospital pharmacists can now call on a unique new web-based tool, PharmacyView, to help them provide a more responsive, effective and precise service to patients

PharmacyView has been developed by Nugensis, a leading UK IT company with a particular interest in health and social care, in partnership with NHS hospital pharmacists. It is already in use across five NHS Boards in Scotland – Greater Glasgow and Clyde, Lanarkshire, Borders, Tayside and Fife – and there is significant interest from others. Nugensis believes that PharmacyView is just as relevant to hospitals in the rest of the UK and is currently in the final stages of discussions with several hospital trusts in England.

 

May 4, 2016
Hospital pharmacists can now call on a unique new web-based tool, PharmacyView, to help them provide a more responsive, effective and precise service to patients

PharmacyView has been developed by Nugensis, a leading UK IT company with a particular interest in health and social care, in partnership with NHS hospital pharmacists. It is already in use across five NHS Boards in Scotland – Greater Glasgow and Clyde, Lanarkshire, Borders, Tayside and Fife – and there is significant interest from others. Nugensis believes that PharmacyView is just as relevant to hospitals in the rest of the UK and is currently in the final stages of discussions with several hospital trusts in England.

 

May 4, 2016
‘Preventing occupational exposure to cytotoxic and other hazardous drugs’ launched in European Parliament

New policy recommendations on preventing occupational exposure to cytotoxic drugs were launched in the European Parliament on 26 April 2016, an important new initiative designed to protect healthcare professionals working across the EU.

 

April 28, 2016
In guidance published this week NICE has recommended new heart failure drug sacubitril valsartan (Entresto, Novartis), the first drug of its kind, as an option for some people with heart failure

The guidance recommends the £3 per day treatment for this life-threatening condition in over 100,000 people with moderate to very severe symptoms whose heart is only able to pump a reduced amount of oxygenated blood around the body (known as a reduced ejection fraction), and whose heart failure is not controlled by the commonly used drugs, ACE inhibitors or ARBs.

 

April 14, 2016
Swedish Orphan Biovitrum AB and collaboration partner Biogen have received a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency recommending the European Commission to maintain the orphan designation for Alprolix®, a recombinant factor IX Fc fusion protein therapy for the treatment of haemophilia B

April 14, 2016
In patients with IBD, CDI is a key risk factor for both morbidity and mortality, with disease interactions increasing the severity of patients’ colitis

April 14, 2016
New first-in-class inhaled antibiotic for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adults with Cystic Fibrosis now available in Germany and Denmark

Raptor Pharmaceuticals Corp. announced that Quinsair (levofloxacin nebulizer solution) is now available in Germany and Denmark. Quinsair is the first inhaled fluoroquinolone approved in the European Union for the management of chronic pulmonary infections due to P. aeruginosa in adults with cystic fibrosis (CF).1,2 The product is administered twice-daily, stored at room temperature and has a short administration time.

 

April 4, 2016
If approved, TREVICTA® will be the first treatment for schizophrenia to be administered four times a year and will provide the longest dosing interval available for an antipsychotic medication in the European Union

March 31, 2016
First-ever treatment for rare bleeding disorder ‘hereditary factor X deficiency’ approved in Europe

Bio Products Laboratory, Limited (BPL) announced that the European Medicines Agency has granted marketing authorisation for Coagadex. Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency. Coagadex is the first and only treatment licensed specifically for this rare bleeding disorder in Europe.1

March 22, 2016
Ten independent studies validate the growing bank of real-life clinical evidence to support switching patients from the reference infliximab (Remicade®) to biosimilar infliximab

March 21, 2016
The marketing approval of Enstilar® would make it the first fixed combination topical foam treatment for people living with psoriasis vulgaris in the EU

LEO Pharma announced that it received scientific approval of Enstilar® (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0.5mg/g)  for the treatment of psoriasis vulgaris in patients 18 years of age or older. Enstilar® is an alcohol-free foam formulation for the topical treatment for psoriasis vulgaris.1

 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine